Company Focus
Bayer
Latest Bayer News
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company developing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders.
Latest News & Features of interest to Bayer
Biotechnology
Johnson & Johnson (NYSE: JNJ) has received a new European approval for a combination of Rybrevant (amivantamab) plus chemotherapy in lung cancer. 28 June 2024
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines and one biosimilar for approval at its June 2024 meeting. 28 June 2024
Biotechnology
US biotech 2seventy bio yesterday announced the completion of an asset purchase agreement (APA) by Danish diabetes and obesity giant Novo Nordisk. 28 June 2024
Pharmaceutical
Shares in Verona Pharma closed nearly 7% higher on Wednesday. 27 June 2024
Biotechnology
TwoStep Therapeutics, a biotech start-up developing targeted therapies for solid tumors, has officially launched after securing $6.5 million in seed funding. 27 June 2024
Pharmaceutical
CASI Pharmaceuticals (Nasdaq: CASI) has announced a preliminary proposal from its chairman and chief executive, Wei-Wu He, to acquire the company's business operations in China. 27 June 2024
Biotechnology
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of patritumab deruxtecan (HER3-DXd). 27 June 2024
Biotechnology
The UK’s health technology assessor has changed its tune regarding CSL Behring’s Hemgenix (etranacogene dezaparvovec), recommending the product for use in England and Wales. 27 June 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk yesterday revealed that the CLARION-CKD Phase III trial failed to meet its primary endpoint and will be stopped. 27 June 2024
Biotechnology
US biotech Arrowhead Pharmaceuticals yesterday announced a reprioritization of funding for its research pipeline. 26 June 2024
Latest In Brief for Bayer
Latest Ones To Watch News of interest to Bayer
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
13 November 2024
8 November 2024
30 October 2024
28 October 2024
Ones to Watch Companies of interest to Bayer
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze